Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
CONCLUSION: These findings demonstrate sustained daily symptom and HRQoL benefits of FF/UMEC/VI versus BUD/FOR. The inclusion of the CAT may provide data that are readily generalizable to everyday clinical practice.
TRIAL REGISTRATION: ClinicalTrials.gov number: NCT02345161.
FUNDING: GSK.
PMID: 29313286 [PubMed - as supplied by publisher]
Source: Adv Data - Category: Epidemiology Authors: Tabberer M, Lomas DA, Birk R, Brealey N, Zhu CQ, Pascoe S, Locantore N, Lipson DA Tags: Adv Ther Source Type: research
More News: Chronic Obstructive Pulmonary | Corticosteroid Therapy | Epidemiology | Flonase | Respiratory Medicine | Statistics | Study | Symbicort